We are delighted to announce that Dr Christopher Chapman of Imperial College has been awarded a Rosetrees Enterprise Fellowship.  The £180,000 award will fund three years of development of an implantable device to deliver precision chemotherapeutic release. The aim is to significantly improve the efficacy of treatment for hard-to-treat cancers, such as brain and pancreatic cancer, that have shown little increase in survival rates over the last 40 years.  It is also hoped that targeted treatment into tumours, via implanted electrodes, will also lead to a reduction in side effects compared to conventional treatments and hence offer patients a better quality of life.

Dr Chapman is currently in his third year as a post-doctoral biomedical engineering research associate.